EG384585 Inhibitors
EG384585 inhibitors are a class of chemical compounds specifically designed to interfere with the activity of certain enzymes or molecular targets, as defined by the structural and functional attributes associated with the EG384585 scaffold. The core structure of these inhibitors typically features a well-defined aromatic or heterocyclic backbone, which provides the molecular rigidity and spatial orientation required for effective binding to their target site. These inhibitors often possess functional groups capable of forming various types of interactions-hydrophobic, hydrogen bonding, or ionic-with the binding pockets of their targets, facilitating strong and specific interactions. Due to their structure-activity relationship, EG384585 inhibitors demonstrate high selectivity for their target molecules, making them valuable in research and development to modulate specific biochemical pathways.
The design and synthesis of EG384585 inhibitors are often achieved through a combination of rational drug design, structural analysis, and chemical optimization. Structural modifications to the core scaffold and substituent groups are key to enhancing their binding affinity, specificity, and bioavailability. These chemical adjustments allow for fine-tuning of the compound's interaction with its target, optimizing the potency and inhibitory activity. The inhibitors are usually characterized by their ability to alter the conformation or functional state of the target molecule, thereby reducing or halting its enzymatic or binding activity. Given their structural specificity, EG384585 inhibitors are widely used in biochemical studies to probe molecular mechanisms, assess the impact of target inhibition on cellular processes, and further elucidate the role of particular enzymes or receptors in complex biological pathways. The design and application of these inhibitors highlight the importance of structural chemistry in developing tools for molecular intervention and understanding biological regulation at a molecular level.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Mifepristone | 84371-65-3 | sc-203134 | 100 mg | $61.00 | 17 | |
Steroid receptor antagonist inhibiting Scgb1b3. Mifepristone directly inhibits Scgb1b3 by binding to steroid receptors, disrupting its steroid binding activity and potentially impacting extracellular functions. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Inhibitor of steroid synthesis. Ketoconazole indirectly inhibits Scgb1b3 by reducing endogenous steroid levels, potentially impacting its steroid binding activity and extracellular functions through modulation of steroid biosynthesis. | ||||||
Finasteride | 98319-26-7 | sc-203954 | 50 mg | $105.00 | 3 | |
5α-Reductase inhibitor reducing androgen levels. Finasteride indirectly inhibits Scgb1b3 by lowering endogenous androgen levels, potentially impacting its steroid binding activity and extracellular functions through modulation of androgen biosynthesis. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $245.00 $1051.00 | 7 | |
Androgen receptor antagonist. Enzalutamide directly inhibits Scgb1b3 by binding to androgen receptors, potentially disrupting its steroid binding activity and extracellular functions through modulation of androgen receptor signaling. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Mineralocorticoid receptor antagonist. Spironolactone indirectly inhibits Scgb1b3 by blocking mineralocorticoid receptors, potentially impacting its steroid binding activity and extracellular functions through modulation of mineralocorticoid signaling. | ||||||
Flutamide | 13311-84-7 | sc-204757 sc-204757A sc-204757D sc-204757B sc-204757C | 1 g 5 g 25 g 500 g 1 kg | $47.00 $156.00 $171.00 $525.00 $941.00 | 4 | |
Antiandrogen inhibiting androgen receptor. Flutamide directly inhibits Scgb1b3 by binding to androgen receptors, potentially disrupting its steroid binding activity and extracellular functions through modulation of androgen receptor signaling. | ||||||
Anastrozole | 120511-73-1 | sc-217647 | 10 mg | $92.00 | 1 | |
Aromatase inhibitor reducing estrogen levels. Anastrozole indirectly inhibits Scgb1b3 by lowering endogenous estrogen levels, potentially impacting its steroid binding activity and extracellular functions through modulation of estrogen biosynthesis. | ||||||
Trilostane | 13647-35-3 | sc-208469 sc-208469A | 10 mg 100 mg | $228.00 $1217.00 | 2 | |
Inhibitor of steroidogenesis. Trilostane indirectly inhibits Scgb1b3 by reducing overall steroid synthesis, potentially impacting its steroid binding activity and extracellular functions through modulation of steroid biosynthetic pathways. | ||||||
Fludrocortisone | 127-31-1 | sc-207690 | 50 mg | $454.00 | ||
Synthetic mineralocorticoid. Fludrocortisone indirectly inhibits Scgb1b3 by activating mineralocorticoid receptors, potentially impacting its steroid binding activity and extracellular functions through modulation of mineralocorticoid signaling. | ||||||
Dutasteride | 164656-23-9 | sc-207600 | 10 mg | $167.00 | 2 | |
Dual 5α-reductase inhibitor. Dutasteride indirectly inhibits Scgb1b3 by reducing endogenous androgen levels, potentially impacting its steroid binding activity and extracellular functions through modulation of androgen biosynthesis. | ||||||